Key result
Inhibiting SNCA improves cardiac dysfunction, inflammation, and fibrosis in ischemic cardiomyopathy models.
Why the study?
Ischemic cardiomyopathy is associated with high mortality and hospitalization rates, and current treatments are suboptimal, motivating the search for novel therapeutic targets.
SNCA was identified as a key gene in ischemic cardiomyopathy, and its inhibition improved cardiac dysfunction and fibrosis in experimental models, suggesting it as a potential therapeutic target.
Hypothesis-generating for SNCA inhibition in ischemic cardiomyopathy; prospective trials needed before clinical adoption.
Ischemic cardiomyopathy (ICM) is associated with high mortality and hospitalization rates, and current treatments are suboptimal. The aim of this research was to identify novel therapeutic targets for ICM. The datasets GSE57338 and GSE5406 were obtained from the Gene Expression Omnibus (GEO) database. Gene modules were constructed using weighted gene co-expression network analysis (WGCNA), and the three relevant modules associated with ICM were identified. The biological functions and signaling pathways of the genes in these modules were further explored through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Protein-protein interaction (PPI) networks were employed to identify hub genes within these modules. Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression was performed to establish gene models, and 16 genes associated with left ventricular ejection fraction (LVEF) in ICM were identified. The genes were validated in heart tissues from human using quantitative real-time polymerase chain reaction (qRT-PCR). Among them, growth factor receptor-bound protein 14 (GRB14), ubiquitin C-terminal hydrolase L1 (UCHL1), and synuclein alpha (SNCA) were identified as key genes significantly associated with ICM. Additionally, key genes correlated with immune and stromal cell-related types were screened using xCell. In vivo and in vitro experiments demonstrated that inhibiting SNCA could improve cardiac dysfunction, inflammatory infiltration, and fibrosis in ICM. In conclusion, this study identified 16 genes closely related to LVEF and revealed that SNCA was a key gene in ICM, providing potential biomarkers and therapeutic targets for ICM.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied Ischemic cardiomyopathy (ICM). SNCA inhibition was evaluated on Cardiac dysfunction, inflammatory infiltration, and fibrosis. Inhibiting SNCA improved cardiac dysfunction, inflammatory infiltration, and fibrosis in in vivo and in vitro models of ischemic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: